An evaluation of the efficacy and safety of using esketamine for continuous intravenous analgesia after thoracic surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049293

Enrollment

Unknown

Registered

2021-07-29

Start date

2021-08-15

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group 1:Esketamine

Experimental group 2:Esketamine + Sufentanil

Eligibility

Sex/Gender

All

Age

30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing thoracic surgery; 2. Aged 30-75 years, no gender restrictions; 3. ASA I-III class; 4. Learn more about the research situation and voluntarily sign the informed consent form before the research.

Exclusion criteria

Exclusion criteria: 1. Patients with severe complications, mental illness, severe liver and kidney dysfunction, respiratory insufficiency, circulatory instability, etc.; 2. Those who are allergic to the active ingredients of esketamine or the anesthetics used.

Design outcomes

Primary

Measure	Time frame
VAS score;	—

Countries

China

Contacts

Public ContactWu Jie

Jiangqiao Hospital, Jiading District, Shanghai

jasmine1914@126.com+86 18918089106

Outcome results